The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board

PRESS RELEASE

Lund  2 May, 2019 - Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that the Election Committee of Active Biotech AB (publ) proposes that Michael Shalmi and Uli Hacksell are appointed new members of the Board of Directors and that Michael Shalmi is appointed Chairman of the Board of Directors. Mats Arnhög and Magnhild Sandberg have declined re-election.

The Election Committee's proposal to the Annual General Meeting
The Election Committee, which is composed of Mats Arnhög (Chairman of the Board), Johnny Sommarlund (MGA Holding), Tomas Billing (Nordstjernan) and Reza Khiabani (own holdings), proposes the following:

Chairman of the Meeting: attorney-at-law Erik Sjöman.

Number of members and deputy members of the Board of Directors: four ordinary members with no deputies.

Fees payable to the Board of Directors: SEK 500.000 to the Chairman of the Board and SEK 200.000 to each of the other Board members who are not employed by the company. Michael Shalmi may also receive remuneration on market terms for work performed for the company outside the scope of the Board work (for additional information, see below).

Board of Directors: re-election of Peter Sjöstrand and Peter Thelin and appointment of Michael Shalmi and Uli Hacksell as new members of the Board.

Chairman of the Board: Michael Shalmi.

Number of auditors and deputy auditors: one auditor with no deputies.

Fees payable to the auditor: in accordance with approved invoices within the scope of the tender.

Auditor: re-election of KPMG AB.

The proposal regarding auditor is in accordance with the recommendation by the Board of Directors.

Furthermore, the Election committee proposes that the Election Committee for the Annual General Meeting 2020 shall be appointed in accordance with principles corresponding to those previously applied.

Information on the Board members proposed to be appointed
Michael Shalmi, born in 1965 and Danish citizen graduated as a physician from University of Copenhagen and obtained his MBA following studies at Scandinavian International Management Institute in Copenhagen. Previously, Michael Shalmi served as Managing Director and Head of Principal Investments of Novo Holdings A/S. He holds a position as director of the Supervisory Board of Evotec AG, and the Board of Momentum Gruppen A/S.